SPOTLIGHT: FDA says Advancis ready to file

Advancis Pharmaceutical announced that the FDA had informed the drug developer that it had enough data to submit an application for marketing approval of the strep throat therapy Amoxicillin Pulsys. Advancis says it will file for approval in December or January. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.